ASLAN Pharmaceuticals Limited American Depositary Shares

ASLN

Börsenwert 1,7 Mio. $

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole operating subsidiary, ASLAN Pharmaceuticals Pte Ltd (“ASLAN SG”), has filed for voluntary liquidation. The decision follows a comprehensive review by the Board of the Company of ASLAN SG's financial position and strategic alternatives. Effective immediately, all employees of ASLAN SG and fellow subsidiary ASLAN Pharmaceuticals (USA) Inc. have been terminated.

SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff had determined to delist the Company's securities from Nasdaq. Upon consideration by the Company's board of directors, the Company has determined not to request a hearing before the Nasdaq Hearings Panel.

ASLAN Pharmaceuticals (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ASLAN Pharmaceuticals (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

SAN MATEO, Calif. and SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society (ATS) International Conference 2024 in San Diego, California.

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will today host a virtual KOL event, during which Company management will present new data from the interim analysis of the Phase 2 TREK-DX study of eblasakimab in dupilumab-experienced atopic dermatitis (AD) patients. The KOL event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, will begin at 8:00 am ET and participants may register here .

SAN MATEO, Calif. and SINGAPORE, May 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd. (Zenyaku), to establish a framework for a succession of research projects to explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.

SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinion Leader (KOL) Event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, to be held on Tuesday, May 7, 2024 from 8:00 AM ET to 9:00 AM ET.